Research programme: anti-interleukin-1 beta monoclonal antibodies - Apexigen/Epitomics

Drug Profile

Research programme: anti-interleukin-1 beta monoclonal antibodies - Apexigen/Epitomics

Alternative Names: APX 002; TK 002 - Apexigen/Epitomics

Latest Information Update: 27 Mar 2014

Price : $50

At a glance

  • Originator Epitomics
  • Developer Apexigen
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 20 Mar 2014 Preclinical development is ongoing in USA
  • 12 Aug 2010 Epitomics spins-off a new company called Apexigen
  • 12 Aug 2010 Preclinical trials in Inflammation in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top